Insider · CIK 0001840601
Jeff Pavell
Files at SILO (Silo Pharma, Inc.), RKTO (Hoth Therapeutics, Inc.). First filing -, latest -.
In brief
Jeff Pavell files SEC Form 4 as director at SILO (Silo Pharma, Inc.), and also at RKTO (Hoth Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jeff Pavell has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 26, 2026 | RKTO Hoth Therapeutics, Inc. | AGrant or award Optionsderivative | +75,000 | $0.00 | $0 | 75,000 | May 28, 2026 |
| May 23, 2025 | SILO Silo Pharma, Inc. | AGrant or award Options (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | May 27, 2025 |
| Aug 19, 2024 | RKTO Hoth Therapeutics, Inc. | AGrant or award Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Aug 21, 2024 |
| Jan 5, 2024 | RKTO Hoth Therapeutics, Inc. | AGrant or award Optionsderivative | +25,000 | $0.00 | $0 | 25,000 | Jan 8, 2024 |
Questions about Jeff Pavell
Answered from the filings on this page, as of the latest one.
Is Jeff Pavell buying or selling?
Jeff Pavell has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jeff Pavell's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jeff Pavell has 0.
Where does Jeff Pavell file Form 4?
Jeff Pavell has filed Form 4 at SILO (Silo Pharma, Inc.); RKTO (Hoth Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.